Sembill, Stephanie
Ampatzidou, Maria
Chaudhury, Sonali
Dworzak, Michael
Kalwak, Krzysztof
Karow, Axel
Kiani, Alexander
Krumbholz, Manuela http://orcid.org/0000-0002-4416-0394
Luesink, Maaike
Naumann-Bartsch, Nora
De Moerloose, Barbara http://orcid.org/0000-0002-2449-539X
Osborn, Michael http://orcid.org/0000-0002-1288-9930
Schultz, Kirk R. http://orcid.org/0000-0002-0001-6438
Sedlacek, Petr
Giona, Fiorina
Zwaan, Christian Michel
Shimada, Hiroyuki
Versluijs, Birgitta
Millot, Frederic
Hijiya, Nobuko
Suttorp, Meinolf http://orcid.org/0000-0002-9522-8838
Metzler, Markus http://orcid.org/0000-0002-4523-1676
Article History
Received: 6 October 2022
Revised: 24 December 2022
Accepted: 16 January 2023
First Online: 27 January 2023
Competing interests
: AK consulted and received honoraria from Novartis, Bristol Myers Squibb, Pfizer, and research funding from Novartis. BM received institutional funding from Novartis and Incyte. MM received research funding from Roche and consulted for BMS and Novartis. MZ received institutional funding from BMS, Pfizer, Takeda, Abbvie, Kura, Syndax, Jazz, and was a consultant to Novartis, Incyte, Takeda, Gilead, and Sanofi. NH has received research funding from Pfizer and Novartis, served on the data monitoring committee for Incyte and Novartis, and has been a consultant for Stemline Therapeutics. All other authors declared no conflict of interest.